Residency · Residency · Nephrology

Polycystic Kidney Disease

Introduction

Autosomal dominant polycystic kidney disease is the most common inherited kidney disease, affecting approximately 1 in 400 to 1 in 1000 individuals worldwide. It is the fourth leading cause of ESRD, accounting for approximately 5 percent of the ESRD population. ADPKD is characterized by the progressive development and expansion of bilateral renal cysts, leading to massive kidney enlargement and eventual renal failure. Importantly, ADPKD is a systemic disorder with extrarenal manifestations including hepatic cysts, intracranial aneurysms, cardiac valvular disease, hernias, and diverticulosis.

Genetics

PKD1 (Chromosome 16p13.3)

Mutations in the PKD1 gene account for approximately 78 percent of ADPKD cases. PKD1 encodes polycystin-1, a large transmembrane glycoprotein consisting of 4302 amino acids that functions as a mechanosensor and signaling molecule. PKD1 mutations produce a more severe phenotype with earlier onset of ESRD, at a mean age of 54 years. Truncating mutations within PKD1 are associated with the worst prognosis.

PKD2 (Chromosome 4q22.1)

PKD2 mutations account for approximately 15 percent of cases and encode polycystin-2, a calcium-permeable cation channel belonging to the transient receptor potential family. The PKD2 phenotype is milder, with later onset of ESRD at a mean age of 74 years, fewer cysts, and smaller kidneys at equivalent ages compared to PKD1.

Other Genes

Additional genes implicated in ADPKD include GANAB, encoding the glucosidase II alpha subunit and accounting for approximately 0.3 percent of cases with a milder phenotype, and DNAJB11, which causes an atypical form of ADPKD characterized by small kidneys and interstitial fibrosis. PKD1 hypomorphic alleles, when present in trans with truncating mutations, can cause very early-onset disease.

Autosomal Recessive PKD (ARPKD)

Autosomal recessive PKD results from mutations in the PKHD1 gene on chromosome 6p12, which encodes fibrocystin/polyductin. ARPKD presents in neonates and infants with bilateral renal enlargement and congenital hepatic fibrosis. The cysts arise from collecting duct ectasia and are characteristically radially oriented. Severe cases present with pulmonary hypoplasia and Potter sequence. Milder forms may present later in childhood or adolescence.

Pathogenesis

Cyst Formation (Two-Hit Model + Threshold Model)

Cyst formation in ADPKD is explained by two complementary models. The two-hit model posits that a germline mutation in PKD1 or PKD2 serves as the first hit, with somatic loss of the remaining allele constituting the second hit that initiates cyst formation. The threshold model proposes that cystogenesis occurs when functional polycystin levels fall below a critical threshold, even without complete loss of the second allele. Only approximately 1 to 2 percent of nephrons form cysts, reflecting the stochastic nature of the second hit events.

Cellular Mechanisms

Polycystin-1 and polycystin-2 form a complex on the primary cilium, endoplasmic reticulum, and plasma membrane, where they function in mechanosensation and calcium signaling. Primary cilium dysfunction resulting from disruption of the PC1-PC2 complex leads to aberrant downstream signaling. Loss of polycystin function results in increased intracellular cyclic AMP accumulation, which drives both cell proliferation and CFTR-mediated chloride secretion into the cyst lumen, promoting fluid accumulation and cyst expansion. mTOR activation occurs because PC1 normally inhibits this pathway, and its loss promotes cell proliferation. Wnt signaling dysregulation further promotes cyst growth. The vasopressin/V2 receptor pathway is particularly important therapeutically: AVP stimulates cAMP production in collecting duct cells, driving cyst growth, which forms the basis for tolvaptan therapy.

<image>Cell biology diagram of ADPKD pathogenesis centered on a renal tubular epithelial cell with a primary cilium. Show the polycystin-1 (PC1) and polycystin-2 (PC2) complex on the primary cilium and how it senses luminal fluid flow. Depict the downstream signaling consequences of PC1/PC2 dysfunction: (1) increased cAMP levels from upregulated V2R signaling and loss of calcium-mediated PDE activity; (2) cAMP-driven CFTR chloride secretion causing fluid secretion into the cyst lumen; (3) mTOR pathway activation driving cell proliferation; (4) Ras/MAPK/ERK pathway activation. Show the therapeutic targets: tolvaptan blocking V2R, mTOR inhibitors blocking mTOR, and the role of reduced water intake in lowering AVP. Include an inset showing normal vs cystic tubular epithelium with reversed cell polarity (Na-K-ATPase mislocalization to apical membrane).</image>

Clinical Manifestations

Renal

Progressive cyst growth causes kidney volume to increase at a rate of approximately 5 to 6 percent per year, and total kidney volume correlates with subsequent GFR decline. GFR remains relatively preserved until significant parenchymal loss has occurred, often remaining normal until the fourth or fifth decade of life due to compensatory hyperfiltration in unaffected nephrons. Hypertension is present in 60 to 70 percent of patients before any decline in GFR, driven by RAAS activation from cyst compression of the renal vasculature. Flank pain occurs from cyst hemorrhage, cyst infection, or nephrolithiasis, which affects 20 to 30 percent of patients and typically involves uric acid and calcium oxalate stones. Gross hematuria from cyst rupture is generally self-limited and managed conservatively. Cyst infection presents with fever, flank pain, and elevated white blood cell count; CT or PET-CT may be needed for localization. Treatment requires antibiotics that penetrate cyst walls, specifically fluoroquinolones or trimethoprim-sulfamethoxazole, as beta-lactams penetrate cyst walls poorly and are ineffective. Nephrolithiasis requires CT for diagnosis, as ultrasound is limited by the presence of cysts.

Hepatic

Hepatic cysts are the most common extrarenal manifestation, present in approximately 80 percent of patients by age 60. They are more common and more severe in women due to estrogen-driven growth. Unlike congenital hepatic fibrosis in ARPKD, hepatic cysts in ADPKD rarely cause hepatic dysfunction. Complications include mass effect producing abdominal distension, early satiety, and dyspnea, as well as cyst infection and rarely cyst rupture. Treatment options for symptomatic massive polycystic liver disease include somatostatin analogues such as octreotide and lanreotide, aspiration-sclerotherapy, surgical cyst fenestration, and liver transplantation for massive disease.

Cardiovascular

Hypertension is the earliest and most common complication of ADPKD, with a blood pressure target of less than 130/80 as established in the HALT-PKD trial. Cardiac valvular abnormalities include mitral valve prolapse in 25 percent and aortic regurgitation. Intracranial aneurysms occur in 8 percent of ADPKD patients compared to 2 percent in the general population, with the prevalence rising to 16 percent in those with a family history of intracranial aneurysm or subarachnoid hemorrhage. Screening with brain MRA is recommended for patients with a family history of ICA or SAH, previous rupture, high-risk occupations such as pilots, pre-surgical evaluation, or significant patient anxiety. Rescreening intervals are every 5 to 10 years if the initial MRA is negative and every 1 to 2 years if an aneurysm is identified. Intervention is generally recommended for aneurysms 7 mm or larger or those that are symptomatic.

Other

Additional extrarenal manifestations include seminal vesicle cysts, pancreatic cysts which are rare, increased prevalence of colonic diverticulosis, and abdominal and inguinal hernias.

Diagnosis

Ultrasonographic Criteria (Pei-Ravine, Updated)

Unified ultrasonographic diagnostic criteria for at-risk individuals, applicable when the specific gene (PKD1 or PKD2) is unknown, require 3 or more cysts (unilateral or bilateral) for ages 15 to 39, 2 or more cysts in each kidney for ages 40 to 59, and 4 or more cysts in each kidney for age 60 and above. Disease can be reliably excluded when fewer than 2 cysts are present in at-risk individuals aged 40 years or older, owing to the high negative predictive value.

Genetic Testing

Genetic testing is indicated when diagnostic uncertainty exists, for family planning purposes, for evaluation of potential living kidney donors from PKD families, for clinical trial eligibility, and for very early-onset disease. Identification of PKD1 versus PKD2 mutations carries important prognostic implications. PKD1 sequencing is technically challenging due to the presence of 6 pseudogenes on chromosome 16.

MRI-Based Total Kidney Volume (TKV)

MRI is the gold standard for assessing cyst burden through measurement of total kidney volume. Height-adjusted TKV serves as a predictor of progression risk. The Mayo Imaging Classification stratifies patients into classes 1A through 1E based on the estimated rate of kidney growth: class 1A indicates slow growth of less than 1.5 percent per year with low ESRD risk, class 1B indicates 1.5 to 3 percent per year, class 1C indicates 3 to 4.5 percent, class 1D indicates 4.5 to 6 percent, and class 1E indicates greater than 6 percent per year with the highest ESRD risk. This classification system is the primary tool for identifying patients likely to benefit from tolvaptan therapy.

Management

General Measures

Blood pressure should be targeted to less than 110/75 mmHg in patients aged 18 to 50 with preserved GFR, based on the HALT-PKD Part A trial which showed a trend toward slowed TKV growth but no GFR benefit with this lower target. For all other patients, a target of less than 130/80 mmHg is appropriate. ACE inhibitors or ARBs are the preferred antihypertensive agents given the central role of RAAS activation in ADPKD-related hypertension. Increased water intake targeting a urine osmolality below 280 mOsm/kg suppresses AVP and thereby reduces cAMP-driven cyst growth, with a practical target of approximately 3 liters per day. Caffeine should be avoided as it stimulates cAMP through phosphodiesterase inhibition. Moderate sodium restriction to less than 2 grams per day is recommended. Contact sports should be avoided due to the risk of cyst rupture in enlarged kidneys.

Tolvaptan (V2 Receptor Antagonist)

Tolvaptan is a selective vasopressin V2 receptor antagonist that blocks AVP-mediated cAMP generation in collecting duct cells. The TEMPO 3:4 trial, published in 2012, demonstrated that tolvaptan significantly slowed TKV growth at 2.8 percent versus 5.5 percent per year and reduced the rate of eGFR decline over 3 years. The REPRISE trial, published in 2017, extended this evidence to later-stage ADPKD in patients with an eGFR of 25 to 65 mL/min. Tolvaptan is FDA-approved for ADPKD at risk of rapid progression, with eligibility criteria including age 18 or above and Mayo class 1C to 1E or an eGFR decline exceeding 2.5 mL/min per year. Dosing follows a split-dose regimen starting at 45 mg in the morning and 15 mg in the evening, titrated to 90/30 mg. The major side effects include aquaresis manifesting as polyuria, nocturia, and polydipsia, requiring patients to maintain adequate water intake, and hepatotoxicity with ALT elevation exceeding 3 times the upper limit of normal occurring in 3 to 5 percent. Monthly liver function tests are required for the first 18 months, followed by quarterly monitoring. Tolvaptan is contraindicated in liver disease and should be avoided in patients unable to maintain adequate hydration.

mTOR Inhibitors

Sirolimus and everolimus showed initially promising preclinical data, but clinical trials including SUISSE-ADPKD and ALADIN failed to demonstrate significant benefit on TKV or GFR, and side effects were limiting. mTOR inhibitors are not recommended for ADPKD treatment.

Somatostatin Analogues

Octreotide LAR and lanreotide inhibit cAMP in both hepatic and renal cysts. The DIPAK-1 trial evaluating lanreotide showed modest slowing of TKV growth but no GFR benefit, with gastrointestinal side effects being a limiting factor. The primary role of somatostatin analogues is in the management of polycystic liver disease, where they achieve meaningful hepatic cyst volume reduction.

<image>Clinical management timeline for ADPKD showing interventions across the disease course from diagnosis to ESRD. At the top, show a graph of kidney volume (TKV) increasing over time and GFR declining. Along the timeline, mark key intervention points: (1) Diagnosis (genetic testing, MRI TKV, Mayo classification). (2) Early disease (age 18-40, preserved GFR): BP control ACEi/ARB target 110/75 if age <50, increased water intake, avoid caffeine, screen for ICA if family history. (3) Progressive disease (Mayo 1C-1E or declining GFR): initiate tolvaptan with split dosing and LFT monitoring; SGLT2 inhibitor if eGFR ≥20. (4) Advanced CKD: CKD-MBD management, anemia, dialysis planning. (5) ESRD: dialysis (PD feasible despite large kidneys) or transplant (native nephrectomy if massive kidneys causing symptoms). Show monitoring intervals: annual eGFR, MRI TKV every 2-3 years, monthly LFTs on tolvaptan.</image>

ADPKD and Transplantation

ADPKD patients achieve excellent transplant outcomes comparable to non-ADPKD recipients. Native nephrectomy is not performed routinely but is indicated for massive kidneys causing mechanical complications, recurrent infections, or the need to create space for the allograft. Nephrectomy can be performed before, during, or after transplantation, though simultaneous nephrectomy carries a higher complication rate. Living related donors from PKD families require genetic testing and imaging to exclude disease; MRI is preferred for donors under age 40, as ultrasound may miss early disease. There is no recurrence of ADPKD in the allograft, as this is a genetic disease of the recipient rather than the donor.

Key Clinical Pearls

• Mayo Imaging Classification (1A-1E) based on htTKV is the primary tool for identifying patients at risk of rapid progression who are candidates for tolvaptan
• Tolvaptan requires rigorous monitoring for hepatotoxicity (monthly LFTs for 18 months) and adequate hydration counseling (patients must drink enough water to compensate for massive aquaresis)
• GFR remains misleadingly normal until late in ADPKD because compensatory hyperfiltration masks ongoing nephron loss; TKV is a more sensitive early marker of disease progression
• Screen for intracranial aneurysm with brain MRA in ADPKD patients with family history of ICA or SAH; prevalence is 4x the general population
• Cyst infections require cyst-penetrating antibiotics (fluoroquinolones, TMP-SMX); beta-lactams penetrate cyst walls poorly and are ineffective

References

1. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (TEMPO 3:4). N Engl J Med. 2012;367(25):2407-2418.
2. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease (REPRISE). N Engl J Med. 2017;377(20):1930-1942.
3. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials. J Am Soc Nephrol. 2015;26(1):160-172.
4. Schrier RW, Abebe KZ, Perrone RD, et al. Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease (HALT-PKD). N Engl J Med. 2014;371(24):2255-2266.
5. Harris PC, Torres VE. Polycystic Kidney Disease. Annu Rev Med. 2009;60:321-337.

Read this lecture as Markdown